<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE patent-document
  PUBLIC "-//MXW//DTD patent-document XML//EN" "http://www.matrixware.com/dtds/patents/v1.2/patent-document.dtd"><patent-document ucid="EP-1371377-A1" country="EP" doc-number="1371377" kind="A1" lang="EN" date="20031217" family-id="36932148" date-produced="20090516" status="new"><bibliographic-data><publication-reference fvid="23908748" ucid="EP-1371377-A1" status="new"><document-id status="new" format="original"><country>EP</country><doc-number>1371377</doc-number><kind>A1</kind><date>20031217</date></document-id></publication-reference><application-reference ucid="EP-02727017-A" status="new" is-representative="NO"><document-id format="epo" status="new"><country>EP</country><doc-number>02727017</doc-number><kind>A</kind><date>20020103</date></document-id></application-reference><priority-claims status="new"><priority-claim ucid="KR-0200001-W" status="new"><document-id format="epo" status="new"><country>KR</country><doc-number>0200001</doc-number><kind>W</kind><date>20020103</date></document-id></priority-claim><priority-claim ucid="KR-20010000691-A" status="new"><document-id format="epo" status="new"><country>KR</country><doc-number>20010000691</doc-number><kind>A</kind><date>20010105</date></document-id></priority-claim></priority-claims><technical-data status="new"><classifications-ipcr><classification-ipcr status="new">A61K  35/12        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr status="new">A61K  35/12        20060101CLI20051220RMJP        </classification-ipcr><classification-ipcr status="new">A61K  35/66        20060101CLI20051220RMJP        </classification-ipcr><classification-ipcr status="new">A61K  35/76        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr status="new">A61K  38/00        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr status="new">A61K  38/00        20060101CLI20051220RMJP        </classification-ipcr><classification-ipcr status="new">A61K  38/19        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr status="new">A61K  38/19        20060101C I20051008RMEP        </classification-ipcr><classification-ipcr status="new">A61K  38/22        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr status="new">A61K  38/22        20060101CLI20051220RMJP        </classification-ipcr><classification-ipcr status="new">A61K  38/39        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr status="new">A61K  38/39        20060101C I20051008RMEP        </classification-ipcr><classification-ipcr status="new">A61K  38/43        20060101C I20051008RMEP        </classification-ipcr><classification-ipcr status="new">A61K  38/48        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr status="new">A61K  48/00        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr status="new">A61K  48/00        20060101CLI20051220RMJP        </classification-ipcr><classification-ipcr status="new">A61P  29/00        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr status="new">A61P  29/00        20060101CLI20051220RMJP        </classification-ipcr><classification-ipcr status="new">A61P  43/00        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr status="new">A61P  43/00        20060101CLI20051220RMJP        </classification-ipcr><classification-ipcr status="new">C07K  14/435       20060101CLI20051220RMJP        </classification-ipcr><classification-ipcr status="new">C07K  14/47        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr status="new">C12N  15/09        20060101AFI20051220RMJP        </classification-ipcr><classification-ipcr status="new">C12N  15/09        20060101CFI20051220RMJP        </classification-ipcr><classification-ipcr status="new">C12N  15/867       20060101A I20051008RMEP        </classification-ipcr><classification-ipcr status="new">C12N  15/867       20060101C I20051008RMEP        </classification-ipcr></classifications-ipcr><classification-ecla status="new"><classification-symbol scheme="EC">A61K  38/19</classification-symbol><classification-symbol scheme="EC">A61K  38/39</classification-symbol><classification-symbol scheme="EC">A61K  38/48K7</classification-symbol><classification-symbol scheme="EC">A61K  48/00D</classification-symbol><classification-symbol scheme="EC">C12N  15/867</classification-symbol><classification-symbol scheme="ICO">K01K267:03A5</classification-symbol><classification-symbol scheme="ICO">K61K35:12</classification-symbol><classification-symbol scheme="ICO">K61K48:00</classification-symbol><classification-symbol scheme="ICO">M07K221:24</classification-symbol><classification-symbol scheme="ICO">M07K319:02</classification-symbol><classification-symbol scheme="ICO">M12N799:02A67</classification-symbol></classification-ecla><invention-title lang="DE" load-source="ep" status="new">ZUSAMMENSETZUNGEN ZUR GENTHERAPIE RHEUMATOIDER ARTHRITIS, DIE EIN GEN, DAS FÜR EIN ANTI-ANGIOGENES PROTEIN ODER TEILE DAVON KODIERT, ENTHALTEN(16.07.02)</invention-title><invention-title lang="EN" load-source="ep" status="new">COMPOSITIONS FOR GENE THERAPY OF RHEUMATOID ARTHRITIS INCLUDING A GENE ENCODING AN ANTI-ANGIOGENIC PROTEIN OR PARTS THEREOF</invention-title><invention-title lang="FR" load-source="ep" status="new">COMPOSITIONS UTILISEES EN THERAPIE GENIQUE DE L'ARTHRITE RHUMATOIDE CONTENANT UN GENE CODANT UNE PROTEINE ANTI-ANGIOGENIQUE OU DES PARTIES DE LADITE PROTEINE</invention-title><citations><patent-citations><patcit ucid="US-5858355-A" status="new"><document-id format="epo" status="new"><country>US</country><doc-number>5858355</doc-number><kind>A</kind></document-id><sources><source name="SEA" category="A" created-by-npl="N"/></sources></patcit><patcit ucid="US-6156304-A" status="new"><document-id format="epo" status="new"><country>US</country><doc-number>6156304</doc-number><kind>A</kind></document-id><sources><source name="SEA" category="A" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1994007524-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1994007524</doc-number><kind>A1</kind></document-id><sources><source name="SEA" category="X" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1998012338-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1998012338</doc-number><kind>A1</kind></document-id><sources><source name="SEA" category="AD" created-by-npl="N"/></sources></patcit></patent-citations><non-patent-citations><nplcit status="new"><text>CHEN QING-RONG ET AL:  "Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice" CANCER RESEARCH, vol. 59, no. 14, 15 July 1999 (1999-07-15), pages 3308-3312, XP002354819 ISSN: 0008-5472</text><sources><source name="SEA" category="X" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1994, OLIVER STEPHEN J ET AL: "Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, Taxol" XP002354830 Database accession no. PREV199497453331 &amp;  CELLULAR IMMUNOLOGY, vol. 157, no. 1, 1994, pages 291-299, ISSN: 0008-8749</text><sources><source name="SEA" category="A" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1997, WOOLEY PAUL H ET AL: "A peptide sequence from platelet factor 4 (CT-112) is effective in the treatment of type II collagen induced arthritis in mice" XP002354828 Database accession no. PREV199799566462 &amp;  JOURNAL OF RHEUMATOLOGY, vol. 24, no. 5, 1997, pages 890-898, ISSN: 0315-162X</text><sources><source name="SEA" category="X" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; March 2002 (2002-03), KIM JONG-MOOK ET AL: "Angiostatin gene transfer as an effective treatment strategy in murine collagen-induced arthritis." XP002354829 Database accession no. NLM11920417 &amp;  ARTHRITIS AND RHEUMATISM. MAR 2002, vol. 46, no. 3, March 2002 (2002-03), pages 793-801, ISSN: 0004-3591</text><sources><source name="SEA" category="T" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>DAVIDOFF A M ET AL:  "RETROVIRAL VECTOR-PRODUCER CELL MEDIATED ANGIOGENESIS INHIBITION RESTRICTS NEUROBLASTOMA GROWTH IN VIVO" MEDICAL AND PEDIATRIC ONCOLOGY, LISS, NEW YORK, NY, US, vol. 35, no. 6, December 2000 (2000-12), pages 638-640, XP001106663 ISSN: 0740-8226</text><sources><source name="SEA" category="X" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>GRISCELLI FRANK ET AL:  "Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 95, no. 11, 26 May 1998 (1998-05-26), pages 6367-6372, XP002354820 ISSN: 0027-8424</text><sources><source name="SEA" category="X" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>JOKI TATSUHIRO ET AL:  "Continuous Endostatin release using alginate-polysine polymer-encapsulated producer cells" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, no. 41, March 2000 (2000-03), pages 524-525, XP008055662 &amp; 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH.; SAN FRANCISCO, CALIFORNIA, USA; APRIL 01-05, 2000 ISSN: 0197-016X</text><sources><source name="SEA" category="X" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>READ TRACY-ANN ET AL:  "Alginate encapsulated genetically engineered producer cells: A new treatment approach for malignant brain tumors" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 40, March 1999 (1999-03), page 688, XP008055660 &amp; 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; PHILADELPHIA, PENNSYLVANIA, USA; APRIL 10-14, 1999 ISSN: 0197-016X</text><sources><source name="SEA" category="X" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>See also references of WO    02053191A1</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>TANAKA ET AL:  "RETROVIRAL AND ADENOVIRAL MEDIATED TRANSDUCTION OF ANGIOSTATIN CDNA INHIBITS ANGIOGENESIS AND TUMOR GROWTH" PROCEEDINGS OF THE 88TH. ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. SAN DIEGO, APR. 12 - 16, 1997, PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, PHILADELPHIA, AACR, US, vol. VOL.38, March 1997 (1997-03), page 264, XP002086443</text><sources><source name="SEA" category="X" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>TANAKA T ET AL:  "Inhibition of angiogenesis and tumor growth following retroviral-mediated transduction of a modified platelet factor 4 cDNA" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 37, no. 0, 1996, page 54, XP008055663 &amp; 87TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; WASHINGTON, D.C., USA; APRIL 20-24, 1996 ISSN: 0197-016X</text><sources><source name="SEA" category="X" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>TANAKA T ET AL:  "Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth" NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 3, no. 4, 1997, pages 437-442, XP002145430 ISSN: 1078-8956</text><sources><source name="SEA" category="X" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>VISTED THERESE ET AL:  "Release of angiostatin from alginate-encapsulated producer cells; a new approach for the treatment of malignant brain tumors" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, no. 41, March 2000 (2000-03), page 258, XP008055661 &amp; 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH.; SAN FRANCISCO, CALIFORNIA, USA; APRIL 01-05, 2000 ISSN: 0197-016X</text><sources><source name="SEA" category="X" created-by-npl="N"/></sources></nplcit></non-patent-citations></citations></technical-data><parties><applicants><applicant format="epo" status="new"><addressbook><name>VIROMED LTD</name><address><country>KR</country></address></addressbook></applicant><applicant format="intermediate" status="new"><addressbook><name>VIROMED LIMITED</name></addressbook></applicant><applicant format="original" status="new"><addressbook><last-name>Viromed Limited</last-name><address><street>Institute for Molecular Biology and Genetics, Seoul National University, San 56-1 Sinlim-dong, Gwanak-gu</street><city>Seoul 151-742</city><country>KR</country></address></addressbook></applicant></applicants><inventors><inventor format="epo" status="new"><addressbook><name>HO SEONG-HYUN</name><address><country>KR</country></address></addressbook></inventor><inventor format="epo" status="new"><addressbook><name>KIM JONG-MOOK</name><address><country>KR</country></address></addressbook></inventor><inventor format="epo" status="new"><addressbook><name>KIM SUN-YOUNG</name><address><country>KR</country></address></addressbook></inventor><inventor format="epo" status="new"><addressbook><name>PARK EUN-JIN</name><address><country>KR</country></address></addressbook></inventor><inventor format="intermediate" status="new"><addressbook><name>HO, SEONG-HYUN</name></addressbook></inventor><inventor format="intermediate" status="new"><addressbook><name>KIM, JONG-MOOK</name></addressbook></inventor><inventor format="intermediate" status="new"><addressbook><name>KIM, SUN-YOUNG</name></addressbook></inventor><inventor format="intermediate" status="new"><addressbook><name>PARK, EUN-JIN</name></addressbook></inventor><inventor format="original" status="new"><addressbook><last-name>HO, SEONG-HYUN</last-name><address><street>1364-25 Seocho 2-dong, Seocho-gu</street><city>137-072 Seoul</city><country>KR</country></address></addressbook></inventor><inventor format="original" status="new"><addressbook><last-name>KIM, JONG-MOOK</last-name><address><street>202-1603 Hyundai APT., 296 Bongcheon 7-dong</street><city>Gwanak-gu, 151-818 Seoul</city><country>KR</country></address></addressbook></inventor><inventor format="original" status="new"><addressbook><last-name>KIM, SUN-YOUNG</last-name><address><street>18-302 Hangangmansion APT., 300-127 Ichon-dong</street><city>Yongsan-gu, 140-724 Seoul</city><country>KR</country></address></addressbook></inventor><inventor format="original" status="new"><addressbook><last-name>PARK, EUN-JIN</last-name><address><street>150-4 Doksan-dong, Geumcheon-gu</street><city>153-010 Seoul</city><country>KR</country></address></addressbook></inventor></inventors><agents><agent format="original" status="new"><addressbook><last-name>Wibbelmann, Jobst, Dr., Dipl.-Chem.</last-name><address><street>Wuesthoff &amp;amp; Wuesthoff, Patent- und Rechtsanwälte, Schweigerstrasse 2</street><city>81541 München</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="KR-0200001-W" status="new"><document-id status="new" format="original"><country>KR</country><doc-number>0200001</doc-number><kind>W</kind></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2002053191-A1" status="new"><document-id status="new" format="original"><country>WO</country><doc-number>2002053191</doc-number><kind>A1</kind><date>20020711</date></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country>AT</country><country>BE</country><country>CH</country><country>CY</country> <country>DE</country><country>DK</country><country>ES</country><country>FI</country><country>FR</country> <country>GB</country> <country>GR</country> <country>IE</country><country>IT</country><country>LI</country><country>LU</country><country>MC</country><country>NL</country><country>PT</country><country>SE</country><country>TR</country></ep-contracting-states></designated-states></international-convention-data></bibliographic-data><abstract lang="EN" load-source="ep" status="new"><p>The present invention relates to the compositions for a gene therapy of rheumatoid arthritis including a gene encoding
an anti-angiogenic protein or parts thereof. More specifically, the present invention provides a gene therapy of rheumatoid arthritis
by preparing a recombinant vector that expresses a gene encoding an anti-angiogenic protein such as angiostatin or parts thereof,
and transplanting the recombinant vector or a cell that is transfected or transduced with the recombinant vector into the affected
area of a patient, and also provides the compositions for the gene therapy. The compositions for the gene therapy according to the
present invention can be used effectively for the treatment of rheumatoid arthritis, for which effective treating methods have not been
developed until now by providing the anti-angiogenic proteins into the knee of a patient continuously to prevent the synovial tissue
hyperplasia and the resulting inflammation.
<img file="00000001.tif" id="img-00000001" he="96" wi="75" img-format="tif" img-content="ad" orientation="unknown" inline="no"/></p></abstract><description lang="EN" load-source="ep" status="new"><heading><b>TECHNICAL FIELD</b></heading><p num="0001">The present invention relates in general to compositions for gene therapy of
rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts
thereof, and more particularly to a gene therapy for treating rheumatoid arthritis by
constructing a recombinant vector including a gene encoding an anti-angiogenic protein
or parts thereof and transplanting the recombinant vector or the cells transfected or
transduced with the recombinant vector into the affected area of a patient, and
compositions for the gene therapy.</p><heading><b>BACKGROUND ART</b></heading><p num="0002">Rheumatoid arthritis is a chronic inflammatory disease involving multiple
joints. The main pathology of the affected synovial tissue consists of the hyperplasia
and the subintimal infiltration of T and B lymphocytes. Such inflammation of the
synovial tissue is thought to be caused by T lymphocyte reactive to an unknown 
autoantigen. Nonetheless, the T lymphocyte infiltrated in the almost tissues does not
show any indication of activation on the surface of cell and also does not almost express
cytokines. In contrast to this, it is observed that both synovial tissue and fluid are
enriched with the cytokines derived from macrophage. These cytokines may include
interleukin-1 (IL-1) which can accelerate the growth of synovial fibroblast and tumor
necrosis factors (TNFs). These experimental results suggest the hypothesis that T
lymphocyte is importantly associated with the induction of inflammation to synovial
tissues and the inflammation is maintained by the cytokines derived from the activated
synovial cells.</p><p num="0003">One of the major intents of rheumatoid arthritis treatment is to prevent the
synovial tissue hyperplasia, because it forms the pannus tissue that irreversibly destroys
the cartilage and bone in the affected joint. Effective drugs for treating rheumatoid
arthritis have not been developed until the present time and the developed drugs can
exhibit limited efficacies. Once arthritis occurs, it causes economic loss as well as
severe pain.</p><p num="0004">Medical treatments of rheumatoid arthritis being used presently are as follows.
The drugs used often for initial treatment are non-steroidal anti-inflammatory drugs
(NSAIDs). These NSAIDs limitedly improve a patient's condition, but cannot prevent
the cartilage destruction of joint area or the progress of disease. Moreover, half the
patients using this treatment should stop the treatment within one year because of 
serious side effect. Next, gold drugs such as gold sodium thiomalate and gold sodium
thiosulfate, or disease modifying anti-rheumatic drugs (DMARDs) such as
penicillamine and anti-malarials are used. These drugs also decrease the progress of
rheumatoid arthritis, but after 5 years of the treatment using DMARDs, only 5-15% of
the patients adhere to use the drugs because the serious side effect can be accompanied.
If the drugs mentioned above are not effective any more, the affected joint area with
rheumatoid arthritis should be replaced by artificial joint by surgical operation.</p><p num="0005">In this manner, most of the treatments of rheumatoid arthritis used until now
were not designed with a particular target molecule and had a limitation of showing
slight effects in most cases. In the meantime, it has been reported that therapeutic
effects appeared by taking notice of inflammation-inducing cytokines such as TNF as a
target molecule for treating the rheumatoid arthritis and introducing an antibody specific
to TNF or a soluble TNF-receptor into the affected area of a patient to result in
inactivation of the TNF (Maini, R.N. <i>et al., Immunol.</i> Rev. 144:195, 1995; Moreland,
LW. <i>et al., N.</i> Engl. J. <i>Med.</i> 337:141, 1997). In company with this, various gene
transfer experiments <i>in vivo</i> are progressing in an animal model of rheumatoid arthritis
with continuously expressing the molecules having an immune inhibitory function.
Consequently, most of the current treatments are directed to correction of the immune
aberration that supposedly drives the synovial cell proliferation. </p><p num="0006">Angiogenesis, the formation of new blood vessels, is one of the earliest
histopathologic findings in rheumatoid arthritis and appears to be required for pannus
development. This neovascularization is thought not only to maintain the chronic
architectural changes via delivery of required blood-borne elements to the pannus, but
also to play an active role in inflammation as a source of both cytokine and protease
activity. The expanded vascular-bed volume resulting from angiogenesis may provide
increased access for inflammatory cells to infiltrate the synovium. Although the
factors specifically promoting angiogenesis in rheumatoid arthritis have not yet been
identified, both synovial tissue and fluid are enriched with angiogenesis-promoting
molecules. These include cytokines, such as basic fibroblast growth factor (bFGF),
interleukin-8 (IL-8), vascular endothelial growth factor (VEGF), and soluble adhesion
molecules, such as E-selectin. These data suggested a therapeutic potential for using
an anti-angiogenic procedure for favorably changing the disease course of rheumatoid
arthritis.</p><p num="0007">Until now a lot of factors that repress angiogenesis have been found. Most of
them are created from the cleavage of protoprotein, and representatively angiostatin,
endostatin and platelet factor-4 and the like have been known.</p><p num="0008">Angiostatin is composed of 98<sup>th</sup> to 440<sup>th</sup> amino acids of plasminogen.
Angiostatin was initially isolated from mice bearing a Lewis lung carcinoma and was
identified as a 38-kDa internal fragment of plasminogen that encompasses the first four 
kringles of the molecule (O'Relly, M. et <i>al., Cell</i> 79:715, 1994). It was reported that
the growth of primary tumors was inhibited effectively by injecting purified angiostatin
hypodermically in six cancer model experiments (O'Relly, M. <i>et al., Nat</i>. <i>Med.</i> 2:689,
1996).</p><p num="0009">Endostatin consists of C-terminal 183 amino acids of collagen XVIII and has an
anti-angiogenic activity. It was reported that the growth of primary tumors was
inhibited effectively by injecting purified endostatin hypodermically in four cancer
model experiments (O'Relly, M. et <i>al., Cell</i> 88:277, 1997).</p><p num="0010">Platelet factor-4 belongs to CXC cytokine family, which consists of
chemotactic polypeptides below 10 kDa, and has an anti-angiogenic activity. It was
reported that the platelet factor-4 inhibited the growth of cancer, such as B-16
melanoma and HCT-116 colon carcinoma (Maion, <i>T. E. et al., Cancer Research,</i>
51:2077,1991).</p><p num="0011">Angiogenesis is known to be associated with various diseases, such as tumor
formation and metastasis, retinitis, angioma, chronic inflammation, intestinal adhesions,
atherosclerosis, rheumatoid arthritis and so on, but it has not yet been verified that anti-angiogenic
factors were effective to all the diseases listed above actually. Only the
tumor inhibitory effects of these factors associated with a particular disease have been
reported (USP 5,856,315, USP 5,733,876, USP 5,792,845, USP 5,854,205, USP
6,024,688). The US patents disclose that the treatment effects for various kinds of 
diseases, such as ovarian carcinoma (HTB161, A2780S), colon carcinoma (MIP,
CACO2), Lewis Lung Carcinoma (LLC), fibrosarcoma (T241), prostate gland
carcinoma (PC-3) and breast carcinoma (MDA-MB), were identified by injecting anti-angiogenic
factors with the type of recombinant protein.</p><p num="0012">Meanwhile, unlike general treating method that applies a toxicity to cells
directly, the treating method, which cures diseases by inhibiting angiogenesis by means
of supplying anti-angiogenic factors as described above, is based on the principle of
inhibiting the cell growth, so anti-angiogenic factors over certain concentration should
be supplied continuously to exhibit effects <i>in vivo.</i> But, the method of supplying anti-angiogenic
factors with the type of recombinant proteins costs too much for
administering proteins continuously, is troublesome and has a problem in that it imparts
toxicity to a patient. Therefore, it has been required to develop a method of supplying
anti-angiogenic factors to the affected area continuously and locally.</p><p num="0013">Accordingly, the present inventors have attempted new approaches for the
probability of the treatment of rheumatoid arthritis by anti-angiogenesis in order to
replace the prior treatment of rheumatoid arthritis having focused on solving the
immunological problems. More particularly, the present inventors obtained the cell
lines for producing representative anti-angiogenic factors such as angiostatin, endostatin 
and platelet factor-4 through inserting their genes into a viral vector and then
transplanting them the affected area of mice induced with rheumatoid arthritis. We also
performed the histological examinations for the level of hyperplasia in synovial cell and
cartilage destruction and the immunological examinations for the concentrations of
cytokines associated with the joint inflammation, as well as macroscopic examination
for joint swelling to obtain the results for the progressive level of rheumatoid arthritis.
The results showed that the incidence of rheumatoid arthritis in our treatment was
remarkably reduced in comparison with the control group. This is to show that our gene
therapy using an anti-angiogenic gene is effective to treatment of rheumatoid arthritis.</p><heading><b>DISCLOSURE OF THE INVENTION</b></heading><p num="0014">It is therefore an object of the present invention to provide compositions for
gene therapy of rheumatoid arthritis including a DNA encoding an anti-angiogenic
protein or parts thereof. More particularly, the present invention provides a
recombinant vector including a DNA encoding an anti-angiogenic protein or parts
thereof, a cell into which the recombinant vector is introduced and compositions for the
gene therapy of rheumatoid arthritis including the recombinant vector or the
recombinant cell as an active ingredient.</p><p num="0015">To accomplish this object, the present invention provides compositions for gene 
therapy including a DNA encoding an anti-angiogenic protein or parts thereof, which
shows therapeutic effects on rheumatoid arthritis.</p><p num="0016">According to the compositions of the present invention, the DNA encoding an
anti-angiogenic protein or parts thereof can be provided with an inserted form in
retroviral vector, adenoviral vector, adeno-associated viral vector, herpes simplex viral
vector or plasmid that can be expressed in an animal cell, or with the form of a
recombinant cell that is collected by transfecting or transducing a cell with the
recombinant vector including the DNA in order to supply anti-angiogenic factor to the
affected area continuously and locally.</p><p num="0017">Furthermore, the present invention provides a gene therapy of treating
rheumatoid arthritis by delivering the compositions to the affected area of a patient.</p><p num="0018">As used herein, the term "anti-angiogenic gene" means a DNA encoding an
anti-angiogenic protein or parts thereof. It is not limited to a natural DNA, but may
include any forms of proper modifications under maintenance of anti-angiogenic
activity and additions of elements for expression regulation if it can be used suitably for
the purpose of the present invention, regardless of whether or not it is obtained by
genetic engineering method or chemical method.</p><p num="0019">Hereinafter, the present invention will be described in detail.</p><p num="0020">The present invention is characterized in that the composition for gene therapy 
of treating arthritis comprises a DNA encoding anti-angiogenic protein or parts thereof
as an active ingredient. The anti-angiogenic gene used in the gene therapy for treating
arthritis according to the present invention is preferably a gene encoding at least one
protein selected from the group consisting of angiostatin, endostatin, platelet factor-4,
thrombospondin-1; thrombospondin-2, METH-1, METH-2 (anti-angiogenic proteins
having metalloprotease domain and thrombospondin domain; Vanzquez <i>F. et al., J. Biol.
Chem.</i> 274(33):23349-57, 1999) and hepatocyte growth factor.</p><p num="0021">Particularly, the anti-angiogenic gene included in the composition for gene
therapy of treating arthritis according to the invention is preferably. the gene encoding
the angiostatin including 98<sup>th</sup> to 440<sup>th</sup> amino acids of human plasminogen and the four
kringles, the gene encoding the endostatin including 1334<sup>th</sup> to 1516<sup>th</sup> amino acids of
human collagen XVIII, or the gene encoding the mouse platelet factor-4 protein.</p><p num="0022">Although an entire amino acid sequence may be used as the anti-angiogenic
factor, a fragment known as having anti-angiogenic activity may also be used. For
example, angiostatin kringle 1-3 fragment may be used for this purpose.</p><p num="0023">The example of the anti-angiogenic gene included in the composition for gene
therapy of treating arthritis according to the invention may preferably be the DNA
derived from human, mouse, rhesus, pig or bovine plasminogen, and more preferably
the cDNA of human angiostatin. The endostatin gene may also preferably be the DNA
derived from human, mouse, rhesus, pig or bovine collagen XVIII, and more preferably 
the cDNA of human endostatin. The preferable embodiments of the invention identified
that the angiostatin and endostatin genes cloned from human foreskin fibroblast (HFF)
are effective to gene therapy for treating arthritis.</p><p num="0024">The recombinant vector included in the composition for gene therapy for
treating arthritis according to the invention also comprises the anti-angiogenic gene. It is
preferable that the recombinant vector further comprises a nucleotide sequence
encoding a signal peptide required for secretion in the upstream or downstream in order
to secrete the protein expressed by the gene out of the cell.</p><p num="0025">The signal peptide may include any signal peptides known as associated to
protein secretion in eukaryotic cell, and may preferably be 18 of amino-terminal amino
acids of human plasminogen represented as the SEQ ID No. 2 or the signal peptide of
mouse immunoglobulin κ chain encoded by the nucleotide sequence represented as
SEQ ID No. 13.</p><p num="0026">For example, as described below in one preferable example according to the
invention, the signal sequence can be functionally connected to the anti-angiogenic gene
by synthesizing a nucleotide including the nucleotide sequence encoding 18 of the
amino-terminal amino acids of human plasminogen and the sequences having restrictive
enzyme cleaving sites, hybridizing it into double helical DNA, and treating it with
restrictive enzyme to insert it into a certain site of target vector. However, the
construction of vector having a signal sequence for producing the secretion type of anti-angiogenic 
protein is not limited to as mentioned above, but may be accomplished by
the method well known in the field of this art.</p><p num="0027">The vector used in the composition for gene therapy of treating arthritis
according to the invention is a vector in which the anti-angiogenic gene can be inserted
to supply the anti-angiogenic factor continuously to the affected area. The vector may
include virus-derived vectors such as retroviral vector, adenoviral vector, adeno-associated
viral vector, and herpes simplex viral vector, plasmids capable of being
expressed in bodies of animals such as pCXN2 (Gene, 108:193-200, 1991) and
PAGE207 (Japan Patent Laid-Open No. Sho6-4684), and their modified vectors.</p><p num="0028">In the preferable example according to the present invention, a viral vector was
prepared, which was to produce angiostatin, endostatin or platelet factor-4 as a anti-angiogenic
factor, using MT5 retroviral vector which had been filed before Korean
Industrial Property Office (KIPO) by the present inventors (Korean Patent Appl. No.
97-48095; KCCM-10205), and the effect for treating arthritis was verified by
experimental results as to mouse using the viral vector. The MT5 retroviral vector is a
vector based on murine leukemia virus (MLV) including mutant noncoding sequence of
human elongation factor 1 (EF 1), without coding sequence derived from virus and is
good in both external gene expressing efficiency and viral titer. That is to say, the vector
is to enhance stability by completely removing the <i>gag, pol</i> and <i>env</i> sequence of MLV,
is to include at the upstream of external gene insertion site, a part of noncoding 
sequence of EF 1a as a noncoding sequence derived from heterogeneous gene for
providing splicing receptor, and is to control splicing efficiency appropriately to
maintain gene expressing highly with also maintaining virus producing concentration
highly.</p><p num="0029">Particularly, in one example of the present invention, angiostatin DNA
fragment encoding 93<sup>rd</sup> to 368<sup>th</sup> amino acids of human plasminogen represented as SEQ
ID No. 2 was obtained from human foreskin fibroblast (HFF) through PCR and was
inserted into pGEM T easy vector to construct pGEM T easy-hASTi vector. The
sequence encoding 18 of amino-terminal amino acids of plasminogen of SEQ ID No. 2
was synthesized as a signal sequence, and was inserted into pGEM T easy-hASTi vector
to construct pGEM T easy-hAST vector. The obtained vector was cleaved with BamHI
to prepare human angiostatin gene fragment connected with the signal sequence, which
was inserted into MTS vector. In the meantime, to prepare cell lines expressing human
angiostatin, MT5-hAST vector DNA was transfected into 293T cell with the plasmid
expressing <i>gag-pol</i> and env gene of murine leukemia virus and then non-cellular virus
was obtained from the cell culture media.</p><p num="0030">The obtained virus was transduced into NIH3T3, and then the cell lines
introduced with retrovirus were selected and cultivated to prepare NIH3T3 cells
expressing human angiostatin protein. By means of the same method, NIH3T3 cells
expressing human endostatin protein and mouse platelet factor-4 protein were prepared 
respectively.</p><p num="0031">Another example of the present invention verified the effect of gene therapy for
arthritis using the cell lines respectively expressing anti-angiogenic proteins such as
human angiostatin protein, human endostatin protein and mouse platelet factor-4 protein.</p><p num="0032">Particularly, a gene therapy to mice without any macroscopic signs of
inflammation in collagen-induced arthritis mouse model was performed. Namely, anti-angiogenic
protein-producing NIH3T3 cell lines mixed with PBS were transplanted in
the knee joint area of rear leg of the arthritis-mouse, and then the progressive level of
arthritis was investigated by measuring joint swelling, synovial hyperplasia, destruction
of cartilage, and joint inflammation-associated cytokine level.</p><p num="0033">The results showed that the swelling level in the knee joint area in case of
transplanting angiostatin-producing NIH3T3 cell lines was remarkably decreased to
27% in comparison that the control group in case of injecting only PBS or transplanting
the cell lines transferred with only MT5 vector was 47% or 67%. The frequency
showing the significant level of IL-1 was also remarkably decreased. The synovial
hyperplasia and cartilage destruction in the knee joint area were also remarkably
decreased. Furthermore, similar results to the transplant of antiostatin producing
NIH3T3 cell lines were obtained when endostatin producing NIH3T3 cell lines and
platelet factor-4 producing NIH3T3 cell lines were transplanted. These results show that
the gene therapy using anti-angiogenic gene according to the present invention is 
effective to suppression and treatment of arthritis.</p><p num="0034">In another example of the present invention, duration of therapeutic effects was
measured. The result showed that therapeutic effect of a single injection lasts for 14
days after treatment.</p><p num="0035">The composition of gene therapy for treating arthritis according to the present
invention can be prepared by preparing viral particles including recombinant DNA
encoding anti-angiogenic protein or cell lines transduced with the viral particles and
mixing them with carriers used in gene therapy (Crystal RG <i>et al., Nature Genet.</i>
8:42-51, 1994).</p><p num="0036">The carriers used in gene therapy may include any carriers generally used in
injection liquid. For example, the carriers may include distilled water, sodium chloride
solutions, the mixtures of sodium chloride and inorganic salts or their similar mixtures,
the solutions of materials such as mannitol, lactose, dextran, and glucose, amino acid
solutions such as glycine and arginine, the mixtures of organic acid solutions or salt
solutions and glucose solutions, and their similar solutions. The injection liquid may be
prepared in the form of solution, suspension or colloidal solution by adding osmotic
modulator, pH controller, vegetable oil such as sesame oil or bean oil, lecithin or
surfactant such as non-ionic surfactant to the carriers in the conventional manners. This
injection may be prepared in the form of powder or lyophilization and then dissolved in
the form of solution before being used. </p><p num="0037">The composition of gene therapy for treating arthritis according to the present
invention may be dissolved in a sterilized carrier, in case of solid phase, if needed,
before treatment of gene therapy, or may be used as it is without further treatment in
case of liquid phase.</p><p num="0038">The composition of gene therapy for treating arthritis according to the present
invention can be absorbed in the synovial cell of blood vessel of target area through the
injection manner that the total daily dose of effective ingredient locally administered to
a patient may range from 1 ng to 1 g or it may be administered once through catheter
after surgical operation.</p><p num="0039">The cell line including anti-angiogenic factor producing vector may be any cell
which has the major histocompatibility complex (MHC) antigen identical or similar to
patient's such that it does not generate histoincompatibility during transplantation. That
the synovial cell of patient's are separated and used for gene transfer is preferable for
excluding histoincompatibility completely.</p><heading><b>BRIEF DESCRIPTION OF THE DRAWINGS</b></heading><p num="0040"><sl><li>Fig. 1 is a schematic diagram that shows the process of preparing the pGEM T-hASTi
vector by cloning human angiostatin gene through PCR and introducing the
cloned gene into pGEM T easy vector, the process of preparing the pGEM T-hAST 
vector by linking the signal sequence obtained through PCR functionally to the
upstream of the angiostatin gene introduced in pGEM T-hASTi vector, and the process
of preparing the MT5-hAST vector by introducing the angiostatin gene linked to the
signal peptide into the <i>Bam</i>HI site of retroviral MT5 vector.</li><li>Fig. 2 is a schematic diagram that shows the structure of a double stranded
DNA produced by hybridizing two synthetic nucleotides, which were prepared to have
the nucleotide sequences represented by SEQ. ID. NO: 5 and SEQ. ID. NO: 6, and the
amino acid sequence of the signal peptide encoded therefrom, in order to obtain a gene
that encodes the signal peptide consisting of N-terminal 18 amino acids of human
plasminogen.</li><li>Fig. 3 shows photographs illustrating the level of hyperplasia by staining with
hematoxylin/eosin, knee joint area in the collagen-induced arthritis (CIA) mice, into
which NIH3T3 cell line expressing angiostatin (B) and NIH3T3 control cell line
transduced with only MT5 vector not including an angiostatin gene (A) are injected,
respectively.</li><li>Fig. 4 shows photographs illustrating the level of cartilage destruction by
staining with Safranin O/fast green, knee joint area in the collagen-induced arthritis
(CIA) mice, into which NIH3T3 cell line expressing angiostatin (B) and NIH3T3
control cell line transduced with only MT5 vector not including an angiostatin gene (A)
are injected, respectively. </li><li>Fig. 5 shows photographs illustrating the neovascularization level investigated
using an antibody specific to CD31, which is surface protein of vascular endothelial cell
by immunohistochemically staining knee joint area in the collagen-induced arthritis
(CIA) mice, into which NIH3T3 cell line expressing angiostatin (B) and NIH3T3
control cell line transduced with only MT5 vector not including an angiostatin gene (A)
are injected, respectively.</li><li>Fig. 6 is a graph showing the measurement results on duration of therapeutic
effects of angiostatin-expressing NIH3T3 cells.

   ▪ : control group

   •:group transplanted with 1×10<sup>5</sup> of angiostatin-expressing NIH3T3 cells

   * : P&lt;0.05      ** : P&lt;0.06</li></sl></p><heading><b>BEST MODE FOR CARRYING OUT THE INVENTION</b></heading><p num="0041">The present invention will hereinafter be described in further detail by
examples. It should however be borne in mind that the present invention is not limited
to or by examples.</p><heading><u style="single">Example 1 : Construction of retroviral vector introduced with a gene encoding
an anti-angiogenic protein</u></heading><heading>(1-1) Construction of retroviral vector introduced with human angiostatin gene</heading><heading>(1-1-1) Cloning of human angiostatin gene (Construction of pGEM T easy-hASTi
vector)</heading><p num="0042">Human angiostatin gene was cloned by extracting RNA from the human
foreskin fibroblast (HFF), obtaining cDNA, and performing PCR. First, RNA was
extracted from the HFF cells by using the Tryzol method (Gibco BRL, USA), and
cDNA was obtained from the extracted RNA by using reverse transcriptase
polymerization reaction. Then, a DNA fragment including human angiostatin gene
was obtained through the PCR by using the cDNA as a PCR template and the synthetic
nucleotides represented by SEQ. ID. NO: 3 and SEQ. ID. NO: 4 as primers. To
perform the PCR, total 100 µl of a mixture solution was prepared by mixing 1 µl of
template DNA, each of 1 µl of 10 pmol/µl primer, 10 µl of 10 mM dNTP, 35 units of
Expand high fidelity enzyme (Gibco BRL, USA) and 10 µl of buffer for enzymes. The
reaction condition for PCR was as follows: 94°C for 1 min, 50°C for 1 min, 72 °C for 1
min 30 sec. The PCR was performed 30 cycles. The amplified angiostatin gene
includes a DNA encoding 93<sup>rd</sup>~368<sup>th</sup> amino acids of human plasminogen represented
by SEQ. ID. NO: 2. The amplified PCR product of about 800 bp was introduced into a
pGEM T easy vector (Promega, WI, USA) to construct a pGEM T easy-hASTi vector
(See Fig. 1). </p><heading>(1-1-2) Linking of signal sequence and construction of retroviral MT5-hAST
vector</heading><p num="0043">To make the protein secreted out of cells after expressed from the human
angiostatin gene cloned in the above Example (1-1-1), a nucleotide sequence encoding a
signal peptide was linked functionally to the upstream of the angiostatin gene. The
signal sequence was introduced into the pGEM T easy-hASTi vector. Particularly, to
prepare a nucleotide sequence encoding N-terminal 18 amino acids of human
plasminogen as a signal peptide, nucleotides represented by SEQ. ID. NO: 5 and SEQ.
ID. NO: 6 were synthesized. The synthetic nucleotides were mixed, incubated for 1
min at 94 °C, and consequently incubated for 1 min 30 sec at 50°C to form a double
stranded DNA by pairing the two synthetic nucleotides each other. As shown in Fig. 2,
the double stranded synthetic nucleotides have <i>Hind</i>III and <i>Bam</i>HI sites in one end, and
<i>Nhe</i>l site in the other end. The nucleotides were introduced into <i>Hind</i>III and Nhel sites
of the pGEM T easy-hASTi vector to construct a pGEM T easy-hAST vector. And
then, the pGEM T easy-hAST vector was digested with <i>Bam</i>HI to obtain human
angiostatin gene linked to the signal.sequence, and the obtained human angiostatin gene
was introduced into the <i>Bam</i>HI site of the MT5 vector (KCCM-10205) to construct a
MT5-hAST vector (Fig. 1). </p><heading>(1-2) Construction of retroviral vector introduced with human endostatin gene</heading><heading>(1-2-1) Cloning of human endostatin gene (Construction of pGEM T easy-hESTi
vector)</heading><p num="0044">Human endostatin gene was cloned by extracting RNA from the human
foreskin fibroblast (HFF), obtaining cDNA, and performing PCR. A DNA fragment
including human endostatin gene was obtained by the same method and under the same
PCR condition as the Example (1-1-1) above, except for using the synthetic nucleotides
represented by SEQ. ID. NO: 9 and SEQ. ID. NO: 10 as primers. The amplified
endostatin gene includes a DNA encoding 1334<sup>th</sup> ~ 1516<sup>th</sup> amino acids of human
collagen XVIII represented by SEQ. ID. NO: 8. The amplified PCR product of about
550 bp was introduced into a pGEM T easy vector (Promega, WI, USA) to construct a
pGEM T easy-hESTi vector.</p><heading>(1-2-2) Linking of signal sequence and construction of retroviral MT5-hEST
vector</heading><p num="0045">To make the protein secreted out of cells after expressed from the human
endostatin gene cloned in the above Example (1-2-1), a nucleotide sequence encoding a
signal peptide was linked functionally to the upstream of the endostatin gene. The signal
sequence was introduced into the pGEM T easy-hESTi vector. Particularly, to prepare
a nucleotide sequence encoding N-terminal 25 amino acids of mouse immunoglobulin 
kappa chain as a signal peptide, PCR was performed by using the pSecTag plasmid
(Invitrogen) DNA as a template, and synthetic nucleotides represented by SEQ. ID. NO:
11 and SEQ. ID. NO: 12 as primers. To perform the PCR, total 100µl of a mixture
solution was prepared by mixing 1µl of template DNA, each of 1µl of 10pmol/µl primer,
10µl of 10 mM dNTP, 3.5 units of Expand high fidelity. enzyme (Gibco BRL, USA) and
10µl of buffer for enzymes. The reaction condition for PCR was as follows: 94°C for
1 min, 50°C for 1 min, 72°C for 1 min 30 sec. The PCR was performed 30 cycles.
The signal sequence of the amplified mouse immunoglobulin kappa chain is represented
by SEQ. ID. NO: 13. The amplified PCR product of about 120 bp was introduced into
a pGEM T easy vector (Promega, WI, USA) to construct a pGEM T easy-SigPep vector.
And then, the pGEM T easy-hESTi vector was digested with <i>Nhe</i>l / <i>Bam</i>HI to obtain
endostatin gene, and the obtained endostatin gene was introduced into the <i>Nhe</i>I / <i>Bam</i>HI
sites of the pGEM T easy-SigPep plasmid to construct a pGEM T easy-hEST vector.
Consequently, the pGEM T easy-hEST plasmid was digested with <i>Bgl</i>II / <i>Bam</i>HI to
obtain human endostatin gene linked to the signal sequence, and the obtained human
endostatin gene was introduced into the <i>Bam</i>HI site of the MT5 vector (KCCM-10205)
to construct a MT5-hEST vector.</p><heading>(1-3) Construction of retroviral vector introduced with mouse platelet factor-4
gene</heading><heading>(1-3-1) Cloning of mouse platelet factor-4 gene (Construction of pGEM T easy-mPF4
vector)</heading><p num="0046">Mouse platelet factor-4 gene was cloned by extracting RNA from the spleen of
the C57BL/6 mouse (Japan SLC, Hamamatsu, Japan), obtaining cDNA, and performing
PCR. First, RNA was extracted from the spleen tissue of the mouse by using the
Tryzol method (Gibco BRL, USA), and cDNA was obtained from the extracted RNA by
using reverse transcriptase polymerization reaction. Then, a DNA fragment including
mouse platelet factor-4 gene was obtained through the PCR by using the cDNA as a
PCR template and the synthetic nucleotides represented by SEQ. ID. NO: 15 and SEQ.
ID. NO: 16 as primers. To perform the PCR, total 100µl of a mixture solution was
prepared by mixing 1µl of template DNA, each of 1µl of 10pmol/µl primer, 10µl of 10
mM dNTP, 35 units of Expand high fidelity enzyme (Gibco BRL, USA) and 10µl of
buffer for enzymes. The reaction condition for PCR was as follows: 94°C for 1min,
50°C for 1min, 72°C for 1min 30sec. The PCR was performed 30 cycles. The
amplified platelet factor-4 gene is represented by SEQ. ID. NO: 14. The amplified
PCR product of about 380 bp was introduced into a pGEM T easy vector (Promega, WI,
USA) to construct a pGEM T easy- mPF4 vector.</p><heading>(1-3-2) Construction of retroviral MT5- mPF4 vector</heading><p num="0047">The pGEM T easy-mPF4 vector prepared in the Example (1-3-1) above was 
digested with <i>EcoRV</i> to obtain the platelet factor-4 gene. The obtained platelet factor-4
gene was digested with <i>Bam</i>HI, treated with Klenow fragment, and then was
introduced into the blunt-ended MT5 vector (KCCM-10205) to construct a MT5- mPF4
vector.</p><heading><u style="single">Example 2: Preparation of cell lines expressing anti-angiogenic protein</u></heading><heading>(2-1) Preparation of cell lines expressing human angiostatin</heading><p num="0048">In order to prepare cell lines expressing human angiostatine, the retrovirus
including the MT5-hAST vector was produced. At first, the MT5-hAST vector DNA
prepared in the example (1-1-2) described above was transfected into 293 T cells with
the plasmid (retrovirus packaging kit ampho catalogue #6161; TAKARA SHUZO CO.,
LTD., SHIGA, Japan) expressing <i>gag-pol</i> and <i>env</i> gene of murine leukemia virus
(MLV) and after 8 hrs, new culture medium was exchanged. After 48 hrs, the cell
culture medium was filtered with 0.45 µm of filter paper to obtain non-cellular virus.</p><p num="0049">The produced MT5-hAST retrovirus was transduced into NIH3T3 cells (ATCC
CRL1658), and then the cells were treated with G418 (1<i>µg</i>/<i>µl</i>, Gibco BRL, USA) for 14
days after 24 hrs to select and cultivate the cell lines introduced with the retrovirus.
Collecting the group of cells selected and cultivated gave rise to preparation of NIH3T3
cell lines expressing human angiostatin protein. </p><heading>(2-2) Preparation of cell lines expressing human endostatin</heading><p num="0050">NIH3T3 cell lines expressing human endostatin protein was prepared according
to the same method as the example (2-1), except using the MT5-hEST vector prepared
in the example (1-2-2) instead of the MT5-hAST vector.</p><heading>(2-3) Preparation of cell lines expressing mousce platelet factor-4</heading><p num="0051">NIH3T3 cell lines expressing platelet factor-4 protein was prepared according
to the same method as the example (2-1), except using the MT5-mPF vector prepared in
the example (1-3-2) instead of the MT5-hAST vector.</p><heading><u style="single">Example 3: Efficacy of gene therapy using anti-angiogenic factors in mouse
collagen-induced arthritis model</u></heading><heading>(3-1) Preparation of mouse collagen-induced arthritis model</heading><p num="0052">Mouse collagen-induced arthritis (CIA) model is an autoimmune type of
arthritis model which shows many characteristics in common with human rheumatoid
arthritis. The collagen-induced arthritis model was prepared by the following method.
DBA/1 mice (Jackson Laboratory, Maine, USA), aged 9-10 weeks at the start of
experiments, were immunized intradermally at the base of the tail with bovine type II
collagen (100 µg; Chondrex, WA, USA) emulsified in Freund's complete adjuvant
(Gibco BRL, NY, USA). On day 21, the animals were boosted with an intradermal 
injection of 100 µg type II collagen. Gradual onset of arthritis normally starts
approximately 4 weeks after initial immunization. In this example, mice that did not yet
have any macroscopic signs of arthritis were chosen at 30 days after the initial
immunization to perform gene therapy.</p><heading>(3-2) Measurement of arthritis progress level</heading><p num="0053">Measurement and detailed decision on indices for measuring arthritis progress
level were performed by the following manner. First, histological analysis was
performed for the knee joint cavity in which the cell lines expressing anti-angiogenic
protein (human angiostatin, human endostatin, and mouse platelet factor-4) were
transplanted. The main phathology of rheumatoid arthritis may be summarized to
consist of the hyperplasia of joint synovial cells and irreversible destruction of cartilage
tissues due to the hyperplasia. Histological analysis is the most effective to decide the
progress level of the synovial cell hyperplasia and cartilage destruction. For this
analysis, knee joints of mice were dissected, fixed in 10% phosphate-buffered formalin,
decalcified in 10% EDTA, and then embedded in paraffin. Standard frontal sections of 7
µm were prepared and stained with either hematoxylin/eosin or Safranin O/fast green
(Bakker A.C. et <i>al., Arthritis and Rheumatism</i> 40:893-900, 1997; Apparailly Florence et
<i>al., J. lmmunol.</i> 160:5213-5220, 1998).</p><p num="0054">The hyperplasia levels of synovial cells were scored based on the results of 
hematoxylin/eosin stain according to the criterion suggested in the published paper
(Apparailly Florence et <i>al., J. Immunol.</i> 160:5213-5220, 1998; Lubberts Erik et <i>al., J.
Immunol.</i> 163:4546-4556, 1999). The scores are 0 in normal condition, 1 in slight
inflammation and faint synovial hyperplasia, and 2 in the formation of pannus and
synovial hyperplasia heavier than severe level. It was decided that arthritis occurred in
the knee if the hyperplasia level of synovial cell was 2 or more.</p><p num="0055">The levels of cartilage destructions were scored based on the results of Safranin
O/fast green stain according to the criterion suggested in the published paper (Lubberts
Erik et al., <i>J. Immunol.</i> 163:4546-4556, 1999). The scores are 0 in normal condition, 1
in vacuolation of cartilage cell and slight loss of proteoglycan, 2 in the observation of
cartilage erosion in addition to the previous, and 3 in cartilage erosions at two or more
regions and destruction of subchondral layer. It was decided that arthritis occurred in the
knee if the level of cartilage destruction was 2 or more.</p><p num="0056">Neovascularization level in the joint area was investigated by performing
immunohistochemical stain using the antibody specific to CD31, a surface protein of
vascular endothelial cell (Xu, M. <i>et al., Molecular Genetics and Metabolism</i> 63:103-109,1998).</p><p num="0057">The progress level of arthritis in the ankle area was determined with
macroscopic sign such as joint swelling and immunological sign such as the expression
amount of inflammation-associated cytokine. The levels of joint swellings were scored 
based on the results of macroscopic signs according to the criterion suggested in the
published paper (Apparailly Florence et <i>al., J. Iminunol.</i> 160:5213-5220, 1998). The
scores are 0 in normal condition, 1 in swelling and slight erythema, 2 in distint swelling
and erythema, and 3 in severe edema accompanied with wound. It was decided that
arthritis occurred in the ankle if the level of joint swelling was 2 or more. It was also
decided to be a serious case of arthritis if the level was 3 or more. The detection of
inflammation-associated cytokine was performed by measuring the expression amount
of mouse interleukine-1 (IL-1), which was known to play an important role during the
progress of arthritis, in the ankle joint with ELISA. (R&amp;D systems, Minneapolis, USA)
according to the instruction of manufacturer. It was decided that arthritis occurred if the
expression amount of interleukine-1 was 10 ng or more per 1g of proteins in the joint
tissue.</p><heading>(3-3) Implementation of gene therapy and analysis of experimental results</heading><heading>(3-3-1) In case of transplanting NIH3T3 cell lines expressing human angiostatin
protein</heading><p num="0058">In one group were selected 15 of mice. The NIH3T3 cell lines expressing
human angiostatin were transplanted by mixing 1 × 10<sup>5</sup> of the NIH3T3 cell lines with 25
<i>µl</i> of PBS solution in aseptic condition and injecting the mixture into the knee joint
cavity of mouse using a syringe of 30 gauge. Into one negative control group, NIH3T3 
cells transferred with only MT5 vector were transplanted, and into another negative
control group, only PBS was injected. After that time, the arthritis progresses were
observed. On day 10 after the transplantation of the cell lines, the progressive levels of
arthritis were measured by the investigation of macroscopic sign such as joint swelling,
histological signs such as joint synovial cell hyperplasia and cartilage destruction, and
immunological sign such as the level of joint inflammation-associated cytokine. The
neovascularization in the joint area was also investigated using immunohistochemical
stain. The results are shown in Table 1 and Figs. 3 through 5.
<tables><table><tgroup cols="5"><tbody><row><entry namest="1" nameend="5"><b>The incidences of arthritis for each item</b></entry></row><row><entry align="center"/><entry align="center">Ankle joint swelling (%)</entry><entry align="center">Synovial cell hyperplasia (%)</entry><entry align="center">Joint cartilage destruction (%)</entry><entry align="center">IL-1 detection

(%)</entry></row><row><entry align="center">PBS</entry><entry align="center">47</entry><entry align="center">65</entry><entry align="center">53</entry><entry align="center">41</entry></row><row><entry align="center">MT5</entry><entry align="center">67</entry><entry align="center">93</entry><entry align="center">67</entry><entry align="center">67</entry></row><row><entry align="center">MT5-hAST</entry><entry align="center">27</entry><entry align="center">47</entry><entry align="center">33</entry><entry align="center">27</entry></row></tbody></tgroup></table></tables></p><p num="0059">As shown in Table 1, in the results of joint swelling in the ankle of mouse rear
leg, the level of joint swelling in case of transplanting the cells expressing angiostatin
was remarkably decreased as compared to those in cases of control groups. Namely,
when the incidence of arthritis was investigated based on the joint swelling, the
incidence of arthritis was seen in 27% in case of transplanting the cells expressing 
angiostatin, while the incidences of arthritis was respectively seen in 67% and 47% in
cases of transplanting the control cell lines and of injecting only PBS. These results
verified that the incidence of arthritis in the cells expressing angiostatin was
significantly decreased.</p><p num="0060">In the results obtained through the investigation of synovial cell hyperplasia in
the knee joint of mouse rear leg as shown in Fig. 3, the growth of synovial cell in case
of transplanting the cells expressing angiostatin was remarkably decreased as compared
to those in cases of the control groups. Namely, when the incidence of arthritis was
investigated based on the synovial cell hyperplasia, the incidence of arthritis was seen in
47% in case of transplanting the cells expressing angiostatin, while the incidences of
arthritis was respectively seen in 93% and 65% in cases of transplanting the control cell
lines and of injecting only PBS. These results verified that the incidence of arthritis in
the cells expressing angiostatin was significantly decreased.</p><p num="0061">In the results obtained through the investigation of the desctruction of cartilage
tissue in the knee joint of mouse rear leg as shown in Fig. 4, the destruction of cartilage
tissue in case of transplanting the cells expressing angiostatin was remarkably decreased
as compared to those in cases of the control groups. Namely, when the incidence of
arthritis was investigated based on the destruction of cartilage tissue, the incidence of
arthritis was seen in 33% in case of transplanting the cells expressing angiostatin, while
the incidences of arthritis was respectively seen in 67% and 53% in cases of 
transplanting the control cell lines and of injecting only PBS. These results verified that
the incidence of arthritis in the cells expressing angiostatin was significantly decreased.</p><p num="0062">In the results of the neovascularization level in the knee joint of mouse rear leg
obtained by performing immunohistochemical stain using antibody specific to CD31, a
surface protein in vascular endothelial cell as shown in Fig. 3, the level of
neovascularization in case of transplanting the cells expressing angiostatin was
remarkably decreased as compared to that in case transplanted with the control cell lines.</p><p num="0063">The concentration of IL-1 in the ankle joint of mouse rear leg in case of
transplanting the cells expressing angiostatin into the knee of the same leg was
remarkably decreased as compared to those in cases of the control groups. Namely, in
the results obtained through the investigation of the frequency in case that the
concentration of IL-1 is 10 ng or more per 1g of the joint tissue, the frequency was 27%
in case of transplanting the cells expressing angiostatin, while the frequency was 67% in
case of transplanting the control cell lines and 41% in case of injecting only PBS. These
results verified that the frequency showing the significant level of IL-1 was remarkably
decreased in the cells expressing angiostatin.</p><p num="0064">The total results described as above showed that the transplantation of the cells
expressing angiostatin into the knee with occurrence of arthritis remarkably decreased
the incidence of arthritis not only in the knee joint but also in the ankle joint of the same
leg. These results may suggest that when a gene therapy is performed in a large joint 
such as knee joint, the treatment effect can be also showed in a small joint such as ankle
joint of the same leg by movements of inflammation-inducible or inflammation-inhibitory
factors along with the flow of fluid connected between the joints.</p><heading>(3-3-2) In case of transplanting NIH3T3 cell lines expressing human endostatin
protein</heading><p num="0065">In one group were selected 15 of mice. The NIH3T3 cell lines expressing
human endostatin were transplanted by mixing 1 × 10<sup>5</sup> of the NIH3T3 cell lines with 25
<i>µl</i> of PBS solution in aseptic condition and injecting the mixture into the knee joint
cavity of mouse using a syringe of 30 gauge. Into one negative control group, NIH3T3
cells transferred with only MT5 vector were transplanted. After that time, the arthritis
progresses were observed, and macroscopic sign such as joint swelling was investigated.
The results are shown in Table 2.
<tables><table><tgroup cols="2"><tbody><row><entry namest="1" nameend="2">The incidences of arthritis</entry></row><row><entry align="center"/><entry align="center">Ankle joint swelling (%)</entry></row><row><entry align="center">MT5</entry><entry align="center">75</entry></row><row><entry align="center">MT5-hEST</entry><entry align="center">23</entry></row></tbody></tgroup></table></tables></p><p num="0066">As shown in Table 2, in the results of joint swelling in the ankle of mouse rear
leg, the level of joint swelling in case of transplanting the cells expressing endostatin 
was remarkably decreased as compared to that in case of the control group. Namely,
when the incidence of arthritis was investigated based on the joint swelling, the
incidence of arthritis was seen in 23% in case of transplanting the cells expressing
endostatin, while the incidence of arthritis was seen in 75% in case of transplanting the
control cell lines. These results verified that the incidence of arthritis in the cells
expressing endostatin was significantly decreased. These results may also suggest that
the gene therapy using endostatin can effectively inhibit the occurrence of arthritis.</p><heading>(3-3-3) In case of transplanting NIH3T3 cell lines expressing mouse platelet
factor-4 protein</heading><p num="0067">In one group were selected 15 of mice. The NIH3T3 cell lines expressing
platelet factor-4 were transplanted by mixing 1 × 10<sup>5</sup> of the NIH3T3 cell lines with 25
µl of PBS solution in aseptic condition and injecting the mixture into the knee joint
cavity of mouse using a syringe of 30 gauge. Into one negative control group, NIH3T3
cells transferred with only MT5 vector were transplanted. After that time, the arthritis
progressions were observed. The progressive levels of arthritis were measured by the
investigation of macroscopic sign such as joint swelling, histological signs such as joint
synovial cell hyperplasia and cartilage destruction, and immunological sign such as the
level of joint inflammation-associated cytokine. The results are shown in Table 3.
<tables><table><tgroup cols="5"><tbody><row><entry namest="1" nameend="5">The incidences of arthritis for each item </entry></row><row><entry align="center"/><entry align="center">Ankle joint swelling (%)</entry><entry align="center">Synovial cell hyperplasia (%)</entry><entry align="center">Joint cartilage destruction (%)</entry><entry align="center">IL-1 detection (%)</entry></row><row><entry align="center">MT5</entry><entry align="center">64</entry><entry align="center">77</entry><entry align="center">54</entry><entry align="center">64</entry></row><row><entry align="center">MT5-hAST</entry><entry align="center">29</entry><entry align="center">43</entry><entry align="center">36</entry><entry align="center">29</entry></row></tbody></tgroup></table></tables></p><p num="0068">As shown in Table 3, in the results of joint swelling in the ankle of mouse rear
leg, the level of joint swelling in case of transplanting the cells expressing platelet
factor-4 was remarkably decreased as compared to that in case of the control group.
Namely, when the incidence of arthritis was investigated based on the joint swelling, the
incidence of arthritis was seen in 29% in case of transplanting the cells expressing
platelet factor-4, while the incidence of arthritis was seen in 64% in case of
transplanting the control cell lines. These results verified that the incidence of arthritis
in the cells expressing platelet factor-4 was significantly decreased.</p><p num="0069">In the results obtained through the investigation of synovial cell hyperplasia in
the knee joint of mouse rear leg, the growth of synovial cell in case of transplanting the
cells expressing platelet factor-4 was remarkably decreased as compared to that in case
of the control group. Namely, when the incidence of arthritis was investigated based on
the synovial cell hyperplasia, the incidence of arthritis was seen in 43% in case of
transplanting the cells expressing platelet factor-4, while the incidence of arthritis was
seen in 77% in case of transplanting the control cell lines. These results verified that the 
incidence of arthritis in the cells expressing platelet factor-4 was significantly decreased.</p><p num="0070">In the results obtained through the investigation of the destruction of cartilage
tissue in the knee joint of mouse rear leg, the destruction of cartilage tissue in case of
transplanting the cells expressing platelet factor-4 was remarkably decreased as
compared to that in case of the control group. Namely, when the incidence of arthritis
was investigated based on the destruction of cartilage tissue, the incidence of arthritis
was seen in 36% in case of transplanting the cells expressing platelet factor-4, while the
incidence of arthritis was seen in 54% in case of transplanting the control cell lines.
These results verified that the incidence of arthritis in the cells expressing platelet
factor-4 was significantly decreased.</p><p num="0071">The concentration of IL-1 in the ankle joint of mouse rear leg in case of
transplanting the cells expressing platelet factor-4 into the knee of the same leg was
remarkably decreased as compared to that in case of the control group. Namely, in the
results obtained through the investigation of the frequency in the case that the
concentration of IL-1 is 10 ng or more per 1g of the joint tissue, the frequency was 29%
in case of transplanting the cells expressing platelet factor-4, while the frequency was
64% in case of transplanting the control cell lines. These results verified that the
frequency showing the significant level of IL-1 was remarkably decreased in the cells
expressing platelet factor-4.</p><p num="0072">The total results described as above showed that the transplantation of the cells 
expressing platelet factor-4 into the knee with occurrence of arthritis remarkably
decreased the incidence of arthritis not only in the knee joint but also in the ankle joint
of the same leg.</p><heading><b><u style="single">Example 4: Measurement for duration of therapeutic effects</u></b></heading><p num="0073">To measure the duration of therapeutic effect for NIH3T3 cell lines expressing
angiostatin, the NIH3T3 cell lines were transplanted by mixing 1 × 10<sup>5</sup> of the NIH3T3
cell lines with 25 µl of PBS solution in aseptic condition and injecting the mixture into
the knee joint cavity of mouse using a syringe of 30 gauge. Into one negative control
group, NIH3T3 cells transferred with only MT5 vector were transplanted.</p><p num="0074">The incidence of serious-grade arthritis in feet (as the assessment criteria of
ankle joint swelling is 3 or more) was measured on every third or fourth day from the
transplant day to the 20<sup>th</sup> day. As shown in Fig. 6, the result showed that the occurrence
of serious-grade arthritis was inhibited up to the 14<sup>th</sup> day after transplantation (P&lt;0.05).
This means that the therapeutic effect can be maintained for 14 days after treatment with
one injection.</p><heading><b>INDUSTRIAL APPLICABILITY</b></heading><p num="0075">The gene therapy for treating rheumatoid arthritis using the genes encoding
anti-angiogenic factors provided by the present invention can significantly inhibit the 
progress of arthritis not only in the macroscopic sign such as joint swelling, but also
immunological and histological signs such as inflammation-associated cytokine level,
synovial cell hyperplasia, and destruction of cartilage tissue. Accordingly, the present
invention can be used to treat arthritis effectively in the situation that no effective
treatment has been suggested for arthritis up to now. <img file="00370001.tif" id="img-00370001" he="221" wi="163" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00380001.tif" id="img-00380001" he="226" wi="163" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00390001.tif" id="img-00390001" he="225" wi="162" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00400001.tif" id="img-00400001" he="225" wi="162" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00410001.tif" id="img-00410001" he="223" wi="163" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00420001.tif" id="img-00420001" he="218" wi="162" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00430001.tif" id="img-00430001" he="218" wi="162" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00440001.tif" id="img-00440001" he="219" wi="162" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00450001.tif" id="img-00450001" he="218" wi="163" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00460001.tif"  id="img-00460001" he="218" wi="163" img-format="tif" img-content="tx"  orientation="unknown"  inline="no"/><img file="00470001.tif"  id="img-00470001" he="212" wi="162" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00480001.tif" id="img-00480001" he="212" wi="162" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00490001.tif" id="img-00490001" he="212" wi="162" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00500001.tif" id="img-00500001" he="216" wi="163" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00510001.tif" id="img-00510001" he="216" wi="163" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00520001.tif" id="img-00520001" he="216" wi="163" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00530001.tif" id="img-00530001" he="216" wi="163" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00540001.tif" id="img-00540001" he="216" wi="163" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00550001.tif" id="img-00550001" he="216" wi="163" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00560001.tif" id="img-00560001" he="216" wi="163" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00570001.tif" id="img-00570001" he="216" wi="163" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00580001.tif" id="img-00580001" he="216" wi="163" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00590001.tif" id="img-00590001" he="216" wi="163" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00600001.tif" id="img-00600001" he="216" wi="163" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00610001.tif" id="img-00610001" he="216" wi="163" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00620001.tif" id="img-00620001" he="216" wi="163" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00630001.tif" id="img-00630001" he="216" wi="163" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00640001.tif" id="img-00640001" he="216" wi="163" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00650001.tif" id="img-00650001" he="216" wi="163" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00660001.tif" id="img-00660001" he="216" wi="163" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00670001.tif" id="img-00670001" he="219" wi="163" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00680001.tif" id="img-00680001" he="219" wi="163" img-format="tif" img-content="tx" orientation="unknown" inline="no"/><img file="00690001.tif" id="img-00690001" he="212" wi="164" img-format="tif" img-content="tx" orientation="unknown" inline="no"/></p></description><claims lang="EN" load-source="ep" status="new"><claim num="1"><claim-text>A composition for gene therapy comprising a DNA encoding an anti-angiogenic
protein or parts thereof, which shows therapeutic effects on rheumatoid
arthritis.</claim-text></claim><claim num="2"><claim-text>The composition according to claim 1, wherein the anti-angiogenic protein is
angiostatin; endostatin, platelet factor-4, thrombospondin-1, thrombospondin-2, METH-1,
METH-2 or hepatocyte growth factor.</claim-text></claim><claim num="3"><claim-text>The composition according to claim 1, wherein the DNA encodes 93rd ~
368th amino acids of plasminogen protein (SEQ. ID. NO:2).</claim-text></claim><claim num="4"><claim-text>The composition according to claim 1, wherein the DNA encodes 1334th ~
1516th amino acids of collagen XVIII protein (SEQ. ID. NO: 8).</claim-text></claim><claim num="5"><claim-text>The composition according to claim 1, wherein the DNA encodes platelet
factor-4 protein represented by SEQ. ID. NO: 14.</claim-text></claim><claim num="6"><claim-text>The composition according to claim 1, wherein the DNA encoding an anti-angiogenic
protein or parts thereof links with a nucleotide sequence encoding a signal
peptide.</claim-text></claim><claim num="7"><claim-text>The composition according to claim 6, wherein the signal peptide has N-terminal
18 amino acids of human plasminogen (SEQ. ID. NO: 2).</claim-text></claim><claim num="8"><claim-text>The composition according to claim 6, wherein the signal peptide is a signal
peptide of mouse immunoglobulin κ chain encoded by a nucleotide sequence
represented by SEQ. ID. NO: 13.</claim-text></claim><claim num="9"><claim-text>The composition according to claim 1, wherein the DNA encoding an anti-angiogenic
protein or parts thereof is provided with an inserted form in retroviral vector,
adenoviral vector, adeno-associated viral vector, herpes simplex viral vector or plasmid
that can be expressed in an animal cell.</claim-text></claim><claim num="10"><claim-text>The composition according to claim 9, wherein the retroviral vector is MT5
vector (KCCM-10205).</claim-text></claim><claim num="11"><claim-text>The composition according to claim 1, wherein the DNA encoding an anti-angiogenic
protein or parts thereof is provided with the form of a recombinant cell that
is collected by transfecting or transducing a cell with a recombinant vector including the
DNA.</claim-text></claim><claim num="12"><claim-text>The composition according to claim 11, wherein the recombinant cell has
an MHC antigen that is identical or similar to that of a rheumatoid arthritis patient.</claim-text></claim><claim num="13"><claim-text>The composition according to claim 11, wherein the recombinant cell is a
synovial cell isolated from a rheumatoid arthritis patient.</claim-text></claim><claim num="14"><claim-text>A method of treating rheumatoid arthritis by delivering the composition for
gene therapy of rheumatoid arthritis according to any of claims 1 to 14 to the affected
area of a patient.</claim-text></claim></claims><copyright>User acknowledges that Matrixware and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement set forth at http://www.matrixware.com/legal/marec/data_licence.html</copyright></patent-document>